The FRI deposition profiles highlight that the MDI/ AeroChamber Plus* Flow Vu* VHC system delivered an appreciably greater percentage of drug to the lung region than either of the two DPIs.
The influence of inhalation flow profile was less with the MDI/VHC system and differed between the two DPIs.
The FRI deposition profiles highlight that the MDI/ AeroChamber Plus* Flow Vu* VHC system delivered an appreciably greater percentage of drug to the lung region than either of the two DPIs.
The influence of inhalation flow profile was less with the MDI/VHC system and differed between the two DPIs.
Medications to manage care of bronchiectasis and NTM patients are often delivered via a nebulizer. This study compares a number of different OPEP/Nebulizer combinations using salbutamol as the modelled medication.
The FRI deposition profiles highlight that the MDI/AeroChamber Plus* Flow-Vu* VHC delivered a significantly greater percentage of drug to the lung region than either of the two DPIs, irrespective of flow rate.
This was reflected in much higher modelled oropharyngeal deposition for the two DPIs.
The influence of inhalation flow profile was significant for one of the DPIs.
Inhaled tobramycin is recommended for use in cystic fibrosis patients for treatment of Pseudomonas aeruginosa infection. This in vitro study looked at antibiotic delivery using a BA nebulizer/compressor system and two BE nebulizer/compressor systems.
Living a full life with Chronic Obstructive Pulmonary Disease (COPD) is more accessible than ever before with today’s online resources. Whether you’re looking for in-depth tutorials, facts, or simple tips on self-management, the web offers information at your fingertips. Here’s a few of our favourite bookmark-worthy websites for you!
Joignez-vous à David Gourde, Inf. et CRE, pour une discussion sur comment vous pouvez aider vos patients à libérer leurs poumons avec un traitement non-pharmacologique.
Cette session a été établie en partenariat avec Alliance Pharma.
Votre conférencier : David Gourde, Inf. B. Sc. CRE Intervenant pivot-réseau en maladies pulmonaires chroniques
Joignez-vous à Dr. Claude Poirier, Pneumologue, pour une discussion sur la santé respiratoire et comment vous pouvez aider vos patients à mieux respirer et améliorer leur qualité de vie avec une approche non-pharmacologique.
Watch Community Respiratory Therapists Jacqueline Turvey and Joanne Terry for an interactive discussion on the benefits of Airway Clearance Therapy (ACT), and why this non-pharmacological treatment should be integrated into the action plans of patients dealing with COPD.
This conversation explores:
✓ The face of COPD in Canada
✓ The link between excess mucus and COPD exacerbations
✓ How to integrate a non-pharmacological approach into your patient's treatment plan
✓ Airway Clearance Therapy (ACT) and how it works
✓ How to manage mucus with OPEP therapy
✓ Tips for overcoming obstacles &am
Est-ce une MPOC, une Fibrose, de l’Asthme…NON, C’est une bronchiectasie! Plein feux sur une meilleur prise en charge de cette pathologie!
Joignez-vous à Isabelle LeClerc, Infirmière praticienne, pour une discussion accréditée sur la bronchiectasie afin d'en savoir plus sur ce qui rend cette maladie respiratoire unique. Ensemble, nous découvrirons comment vous pouvez aider vos patients atteints de bronchiectasie à mieux respirer grâce à une approche non-pharmacologique ainsi qu’une bonne autogestion pour finalement améliorer leur qualité de vie.
Join Dr. Sacha Bhinder, HBSc, MD, FRCPC, for a review of inhaled delivery device products that are available in Canada, and how to foster customized care when choosing the most appropriate device for your patient.
Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.
In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.
By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.
COPD/chronic bronchitis patients given an Aerobika* OPEP device compared to an alternative OPEP device had delayed time to re-admission. This supports use of the Aerobika* OPEP device as an add-on to usual care post-exacerbation and highlights differences in OPEP device effectiveness.
From a UK perspective, BUD/F delivered via an MDI + VHC offers an economic benefit for the treatment of patients with mild asthma. Further analysis is required to determine if there would be any quality-adjusted life-year (QALY) effects based on the chosen intervention.
While it’s one of the most anticipated seasons of the year, summer can also be the most difficult season for Canadians living with COPD (chronic obstructive pulmonary disease). We want to help you make the most of it! Here’s what you need to know about summer, and how you can enjoy yours this year.
More consistent dose delivery was achieved with the breath actuated technology rather than breath enhanced. Delivering medication only when the patient inhales would result in more stable therapy if I:E ratio was to change with disease< progression or if the patient took breaks to talk during treatment.
COPD/chronic bronchitis patients given an Aerobika* OPEP device compared to an alternative OPEP device had delayed time to re-admission. This supports use of the Aerobika* OPEP device as an add-on to usual care post-exacerbation and highlights differences in OPEP device effectiveness.
Results from this study demonstrate a reduction in the proportion of patients requiring COPD/chronic bronchitis related readmission within 30 days and 12 months of the Aerobika® OPEP device therapy initiation compared to an alternative OPEP device.
This further supports the use of the Aerobika®OPEP device as an add-on to usual care to manage COPD/chronic bronchitis patients post-exacerbation and highlights that not all OPEP devices are the same in terms of 30-day and 12-month readmissions
